(Q36671332)

15 August 2017

Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine (English)

1 reference

15 August 2017

0 references

0 references

1 reference

1 reference

https://api.crossref.org/works/10.1038/SJ.BJC.6601263

21 March 2024

author name string

C. Ziske

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14562009

21 March 2024

C. Schlie

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14562009

21 March 2024

M. Gorschlüter

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14562009

21 March 2024

A. Glasmacher

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14562009

21 March 2024

U. Mey

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14562009

21 March 2024

J. Strehl

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14562009

21 March 2024

T. Sauerbruch

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14562009

21 March 2024

I. G H. Schmidt-Wolf

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14562009

21 March 2024

language of work or name

English

0 references

publication date

1 October 2003

1 reference

PMCID

2394360

15 August 2017

20 October 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14562009

full work available at URL

21 March 2024

https://www.nature.com/articles/6601263.pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14562009

https://europepmc.org/articles/PMC2394360

21 March 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14562009

https://europepmc.org/articles/PMC2394360?pdf=render

21 March 2024

file format

Portable Document Format

online access status

open access

content deliverer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14562009

http://www.nature.com/articles/6601263.pdf

21 March 2024

file format

Portable Document Format

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1038/SJ.BJC.6601263

http://www.nature.com/articles/6601263

21 March 2024

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1038/SJ.BJC.6601263

British Journal of Cancer

21 March 2024

published in

1 reference

15 August 2017

89

1 reference

15 August 2017

8

1 reference

15 August 2017

1413-1417

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6601263

15 August 2017

0 references

cites work

Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394360

Gemcitabine--a safety review

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394360

Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394360

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394360

Chemotherapy for pancreatic carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394360

A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394360

Phase II study of gemcitabine in patients with advanced pancreatic cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394360

Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394360

The clinical utility of the CA 19-9 tumor-associated antigen.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394360

Colorectal carcinoma antigens detected by hybridoma antibodies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394360

The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394360

Tumor markers in evaluating the response to radiotherapy in unresectable pancreatic cancer.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394360

Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2394360

Nonparametric Estimation from Incomplete Observations

20 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6601263

CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer

21 January 2018

1 reference

12 December 2020

CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer

1 reference

12 December 2020

Prognostic value of CA 19-9 serum course in pancreatic cancer

1 reference

12 December 2020

CA19-9: a pedictor of response in pancreatic cancer treated with gemcitabine and cisplatin

1 reference

12 December 2020

Neuroendocrine-like differentiation in patients with pancreatic carcinoma

1 reference

12 December 2020

Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas.

1 reference

12 December 2020

1 reference

12 December 2020

Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma

1 reference

12 December 2020

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

1 reference

12 December 2020

Identifiers

DOI

1 reference

PMCID

2394360

Dimensions Publication ID

15 August 2017

0 references

1 reference

15 August 2017

1 reference

PMCID

2394360